Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.71 USD | -0.78% | +1.52% | -12.86% |
10/05 | Bristol-Myers Squibb Says Phase 3 Trial of Opdivo in Lung Cancer Fails to Meet Primary Endpoint | MT |
10/05 | Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint | DJ |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.86% | 9.13TCr | |
+31.06% | 68TCr | |
+30.35% | 59TCr | |
-3.42% | 36TCr | |
+18.02% | 33TCr | |
+4.27% | 28TCr | |
+15.53% | 24TCr | |
+10.16% | 21TCr | |
-8.14% | 20TCr | |
+8.12% | 17TCr |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- Transcript : Bristol-Myers Squibb Company Presents at 2023 American Society of Clinical Oncology Annual Meeting, Jun-02-2023 through Jun-06-2023